

Jubbonti[®] (denosumab-bbdz) – First-time interchangeable biosimilar launch

- On June 2, 2025, [Sandoz launched Jubbonti \(denosumab-bbdz\)](#), biosimilar and *interchangeable* to Amgen's [Prolia[®] \(denosumab\)](#).
 - Jubbonti is available at a list price (Wholesale Acquisition Cost [WAC]) 14% below the current Prolia list price (\$1,604.13 per package).
- Jubbonti was [FDA-approved](#) in March 2024.
- Additional biosimilars to Prolia have been approved with pending launch dates:
 - Samsung Bioepis' Ospomyv[™] (denosumab-dssb)
 - Celltrion's Stoboclo[®] (denosumab-bmwo)
 - Fresenius Kabi's Conexxence[®] (denosumab-bnht).
- Jubbonti and Prolia share the following indications:
 - Treatment of postmenopausal women with osteoporosis at high risk for fracture
 - Treatment to increase bone mass in men with osteoporosis at high risk for fracture
 - Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
 - Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
 - Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
- Like Prolia, Jubbonti carries a boxed warning for severe hypocalcemia in patients with advanced kidney disease.